Dear Shareholder,
We have just announced positive results from two pivotal phase 3 studies with VESNEO (latanoprostene bunod), a novel nitric
oxide-donating prostaglandin F2-alpha analog discovered in our Research laboratories in Milan and licensed to Bausch +
Lomb in 2010 for the potential treatment of glaucoma and ocular hypertension. We believe VESNEO has the potential to
become the leading brand in the glaucoma market. These highly promising results are the latest sign of our success in building
an international ophthalmology company. Recently we also acquired Doliage, a privately-held French company with an
established, profitable business in France, and the innovative Carragelose® anti-viral eye drop, which could be launched in
Europe within two years, pending CE marking, for treatment of viral conjunctivitis.
In July we announced our intention to acquire Aciex Therapeutics, Inc in the U.S, which will enable Nicox to significantly
expand our therapeutic pipeline to target major ophthalmic conditions including inflammation and allergy. It will give us
another important phase 3 product – AC-170 for allergic conjunctivitis – in addition to VESNEO. The Board of Directors has
convened an EGM notably to approve the acquisition, to be held on first call on October 22, 2014, and, if the 25% threshold is
not reached, on second call on November 5, 2014. To help us achieve this major step in building long-term shareholder value,
we need your full support through your vote. You may vote by proxy, by internet or by attending the EGM in person on
October 22, 2014, in Sophia Antipolis. If you wish to participate and have not received the documents, or if you have any
questions about the voting process, please call the phone line dedicated to the EGM at +33.4.97.24.53.14 or contact our
Investor Relations team at
[email protected].
In light of these recent exciting developments, we would like to invite you to an information meeting on October 13, 2014
at 6 pm at the UNA Hotel Cusani, meeting room Mirò, Via Cusani 13, Milan (+39.02.85.601) to give you the opportunity to
ask questions about Nicox, our strategy and the proposed acquisition of Aciex